173 related articles for article (PubMed ID: 16724420)
21. Is globotriaosylceramide a useful biomarker in Fabry disease?
Young E; Mills K; Morris P; Vellodi A; Lee P; Waldek S; Winchester B
Acta Paediatr Suppl; 2005 Mar; 94(447):51-4; discussion 37-8. PubMed ID: 15895713
[TBL] [Abstract][Full Text] [Related]
22. Effect of globotriaosyl ceramide fatty acid alpha-hydroxylation on the binding by verotoxin 1 and verotoxin 2.
Binnington B; Lingwood D; Nutikka A; Lingwood CA
Neurochem Res; 2002 Aug; 27(7-8):807-13. PubMed ID: 12374217
[TBL] [Abstract][Full Text] [Related]
23. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
Furujo M; Kubo T; Kobayashi M; Ohashi T
Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
[TBL] [Abstract][Full Text] [Related]
24. Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients.
Heywood WE; Doykov I; Spiewak J; Hallqvist J; Mills K; Nowak A
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2726-2735. PubMed ID: 31319156
[TBL] [Abstract][Full Text] [Related]
25. Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease.
Ishii S; Taguchi A; Okino N; Ito M; Maruyama H
J Biol Chem; 2020 Apr; 295(17):5577-5587. PubMed ID: 32179651
[TBL] [Abstract][Full Text] [Related]
26. Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease.
Tajima Y; Kawashima I; Tsukimura T; Sugawara K; Kuroda M; Suzuki T; Togawa T; Chiba Y; Jigami Y; Ohno K; Fukushige T; Kanekura T; Itoh K; Ohashi T; Sakuraba H
Am J Hum Genet; 2009 Nov; 85(5):569-80. PubMed ID: 19853240
[TBL] [Abstract][Full Text] [Related]
27. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
28. Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease.
Shin YJ; Jeon YJ; Jung N; Park JW; Park HY; Jung SC
Mol Med Rep; 2015 Oct; 12(4):5049-57. PubMed ID: 26135632
[TBL] [Abstract][Full Text] [Related]
29. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513
[TBL] [Abstract][Full Text] [Related]
30. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
31. Different binding property of verotoxin-1 and verotoxin-2 against their glycolipid receptor, globotriaosylceramide.
Itoh K; Tezuka T; Inoue K; Tada H; Suzuki T
Tohoku J Exp Med; 2001 Dec; 195(4):237-43. PubMed ID: 11908825
[TBL] [Abstract][Full Text] [Related]
32. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.
Ivanova MM; Changsila E; Iaonou C; Goker-Alpan O
PLoS One; 2019; 14(1):e0210617. PubMed ID: 30633777
[TBL] [Abstract][Full Text] [Related]
33. Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 10(5)- to 10(6)-fold increased cell sensitivity to verocytotoxin. Role of p-glycoprotein in glycolipid synthesis.
Lala P; Ito S; Lingwood CA
J Biol Chem; 2000 Mar; 275(9):6246-51. PubMed ID: 10692420
[TBL] [Abstract][Full Text] [Related]
34. Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice.
Meng XL; Day TS; McNeill N; Ashcraft P; Frischmuth T; Cheng SH; Liu ZP; Shen JS; Schiffmann R
J Inherit Metab Dis; 2016 May; 39(3):447-455. PubMed ID: 26960552
[TBL] [Abstract][Full Text] [Related]
35. Fabry disease: renal sphingolipid distribution in the α-Gal A knockout mouse model by mass spectrometric and immunohistochemical imaging.
Kuchar L; Faltyskova H; Krasny L; Dobrovolny R; Hulkova H; Ledvinova J; Volny M; Strohalm M; Lemr K; Kryspinova L; Asfaw B; Rybová J; Desnick RJ; Havlicek V
Anal Bioanal Chem; 2015 Mar; 407(8):2283-91. PubMed ID: 25542581
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.
Valbuena C; Leitão D; Carneiro F; Oliveira JP
Virchows Arch; 2012 Feb; 460(2):211-21. PubMed ID: 22205110
[TBL] [Abstract][Full Text] [Related]
37. Determination of globotriaosylceramide in plasma and urine by mass spectrometry.
Krüger R; Bruns K; Grünhage S; Rossmann H; Reinke J; Beck M; Lackner KJ
Clin Chem Lab Med; 2010 Feb; 48(2):189-98. PubMed ID: 19958207
[TBL] [Abstract][Full Text] [Related]
38. A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis.
Taguchi A; Maruyama H; Nameta M; Yamamoto T; Matsuda J; Kulkarni AB; Yoshioka H; Ishii S
Biochem J; 2013 Dec; 456(3):373-83. PubMed ID: 24094090
[TBL] [Abstract][Full Text] [Related]
39. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients.
Manwaring V; Boutin M; Auray-Blais C
Anal Chem; 2013 Oct; 85(19):9039-48. PubMed ID: 23968398
[TBL] [Abstract][Full Text] [Related]
40. Brefeldin A and filipin distinguish two globotriaosyl ceramide/verotoxin-1 intracellular trafficking pathways involved in Vero cell cytotoxicity.
Khine AA; Tam P; Nutikka A; Lingwood CA
Glycobiology; 2004 Aug; 14(8):701-12. PubMed ID: 15102715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
